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a  b  s  t  r  a  c  t
Background: Mycosis fungoides (MF) is an extranodal, indolent non-Hodgkin lymphoma of T
cell  origin. Even with the establishment of MF staging, the initial treatment strategy often
remains unclear.
Aim: The aim of this study was to review the clinical results of total skin electron beam
therapy (TSEBT) for MF in adults published in English language scientific journals searched
in  Pubmed/Medline database until December 2012.
Results: MF is very sensitive to radiation therapy (RT) delivered either by photons or by elec-
trons. In limited patches and/or plaques local electron beam irradiation results in good
outcomes besides the fact of not being superior to other modalities. For extensive patches
and/or plaques data suggest that TSEBT shows superior response rates. The cutaneous dis-
ease  presentation is favorably managed with radiotherapy due to its ability to treat the
full thickness of deeply infiltrated skin. For generalized erythroderma presentation, TSEBT
seems to be an appropriate initial therapy. For advanced disease, palliation, or recurrence
after  the first radiotherapy treatment course, TSEBT may still be beneficial, with acceptable
toxicity. Recommended dose is 30–36 Gy delivered in 6–10 weeks.Conclusion: TSEBT can be used to treat any stage of MF. It also presents good tumor response
with symptoms of relief and a palliative effect on MF, either after previous irradiation or
failure of other treatment strategies.
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.  Background
ycosis fungoides (MF) is an extranodal, low grade, indolent
on-Hodgkin lymphoma of T cell caused by skin homing CD4+
ells [1–3].
It develops primarily in the skin, however, can involve
ymph nodes, blood and visceral organs [1]. It is a rare dis-
ase that mainly affects adult over the age of 40 years with
n incidence of 9.6 cases per million, compromising 3000 of
mericans each year [4].
The diagnosis work-up is centered on a complete history
nd physical examination, which includes examination of the
ntire skin and lymph nodes, incisional or excisional skin
iopsies [5].
The most important prognostic factor is the disease stage
Appendix – Tables 1 and 2) [6–8], mainly in what refers to
xtent and type of involvement of the skin and the presence
r absence of extracutaneous disease.
Supplementary material related to this article can be
ound, in the online version, at http://dx.doi.org/10.1016/
.rpor.2013.08.003.
Even with the establishment of MF  staging, the initial treat-
ent strategy often remains unclear, given the limited high
uality published data and heterogeneity of the disease pre-
entation.
.  Aim
he aim of this study was to review the clinical results of total
kin electron beam therapy (TSEBT) for MF  in adults.
.  Materials  and  methods
n electronic literature search was carried out using the
ubmed/Medline search engine with no language or year
estriction, until December 2012. The search strategy was:
Mycosis Fungoides OR Lymphoma OR Non-Hodgkin OR
ymphoma, T-Cell OR Lymphoma, T-Cell, Cutaneous) AND
Radiotherapy OR TSEBT OR EBT OR TSI OR Total Skin electron
eam therapy OR Electron beam therapy OR Total skin irra-
iation). Only English language publications that presented
linical results were selected to carry out this review.
.  Results
adiation therapy (RT) is considered to be one of the most
ffective single treatment modality for MF  [9], which is very
ensitive to radiation delivered either by photons or electrons.
ue to the acute and late toxicity of the use of X-rays for
F treatment, the replacement of photons by electron beamherapy has been shown to be more  appropriate [9]. Electrons
ased therapy has the capability of delivering the radiation
ose up to the superficial layers of the skin while avoiding
eeper tissues, thus being less toxic [10].iotherapy 1 9 ( 2 0 1 4 ) 92–98 93
4.1.  TSEBT  dose
At present, there are no randomized trials comparing low and
high dose TSEBT. Experiences [11–15] up to now demonstrate
that curative management of MF needs total doses of at least
20 Gy and maybe up to 30 Gy or more.  Based on these records,
the European Organization for the Research and Treatment
of Cancer (EORTC) consensus recommended a total dose of
31–36 Gy delivered in 6–10 weeks. Fractions of 1.0–1.5 Gy every
other day are more  tolerable and the dose is calculated at
4 mm depth from the skin surface with low energy electrons
(4–5.5 MeV) [11].
4.2.  Early  stage  disease:  T1N0MO  (IA);  T1N1M0  (IIA);
T2N0M0  (IB)  and  T2N1M0  (IIA)
Initial treatment for patients with T1 disease is based in skin
directed therapies that include topical treatment (chemother-
apy, corticosteroids), phototherapy, local radiation (X-ray or
electron beam) and TSEBT [12]. All of them result in complete
response rates of at least 80% [13–16].
Currently, no randomized trial is available to support supe-
riority of radiation-based therapy over other topical strategies.
Albeit, some institutional experience suggests suitable out-
comes when TSEBT is used. The Hamilton experience [10]
which included 143 stage IA patients treated with TSEBT
showed a complete response of at least 90% associated with a
cause specific survival of 96% and a overall survival of 76% at
15 years of follow up. Results from 32 patients from that study
treated with TSEBT plus psoralen plus ultraviolet A signifi-
cantly (p = 0.03) improved the progression free survival rates
at 5 years of follow-up.
Furthermore, the retrospective Stanford series [17] eval-
uated the long-term results of patients with stage IA MF
managed with TSEBT and analyzed the factors related to
disease progression and the effect of initial therapy on sur-
vival and freedom from relapse. In that series, complete
response rate of at least 90% was observed with TSEBT.
Patients who received TSEBT (n = 34) had a more  favor-
able freedom-from-relapse outcome than those treated with
topical mechlorethamine hydrochloride (nitrogen mustard)
(n = 73; p < 0.05). No significant difference was seen in the long-
term survival between the two groups.
Due to the lack of benefit in overall survival and the side
effects of TSEBT the standard care for patients with IA MF
remains controversial. The use of TSEBT should be indicated
more strongly as a primary therapy to recurrent/refractory or
extensive lesions; the lesions disappear by two to three weeks
after treatment [12,18].
Assessing the group of patients IB and IIA treatment with skin
directed therapies, used alone or in combination is a standard.
The options include: topical chemotherapy, topical corti-
costeroids, TSEBT and phototherapy. Nevertheless these
treatment options have not been prospectively compared.
Regarding TSEBT for T2 patients the complete response
rate, overall survival and progression free survival range
from 76 to 90%, 75–99%, and 12–44%, respectively, at 2.5–15
years of follow-up [11]. These results are excellent when
compared with a complete response rate of 34% for topical
mechlorethamine [19]. Rotational TSEBT was also evaluated
nd ra94  reports of practical oncology a
with good complete response rate and a 5-year overall sur-
vival, favoring T2 stage patients [20,21].
A French series presented the treatment results of 57
patients out of 141 referred to radiotherapy [22]. Of those,
24 were staged as T1 and 33 as T2 patients. A total of 25
received topical therapy before irradiation (TSEBT- 30 Gy over
4 weeks with 6 MeV). Complete response was obtained in
85% of patients with T2 lesions. Thirty-one patients (54.4%)
experienced a skin failure (23 with T2 disease) within 1 year.
For the whole group, 5-year disease free survival was 50%.
The 5/10/15-year overall survival rates were 90%/65%/42%,
respectively. The study also reported the following significant
favorable prognostic factors for overall survival: T1 (p = 0.03),
complete response after first TSEBT (p = 0.04), and age younger
than 60 (p < 0.001) in univariate analysis. Younger age persisted
as a significant prognostic factor on multivariate analysis
(p = 0.001).
Shouman et al. [23] analyzed a total of 40 patients with the
diagnosis of T1/T2 MF  from 1997 to 2002. All patients were
treated with TSEBT (total dose of 35 Gy over 10 weeks). A com-
plete response rate of 87.5% and a 2-year overall disease free
survival of 66% were observed. TSEBT was generally well tol-
erated.
A prospective series published by Kirova et al. [24] analyzed
66 consecutive patients with MF  treated from 1978 to 1996. All
patients received topical and/or systemic therapy, and 30 Gy
TSEBT delivered in 12 fractions was indicated for persistent or
recurrent disease. About one third (36%) of the patients were
stage A (T1N0 or T2), 33% stage B (T2 with more  than 50%
of skin disease), most of them being male (59%). For stage A,
the survival rate at 5-year was 93% and the complete response
rate, 100%. For stage B the 5-year survival rate was 79% and the
complete response rate, 44%. At the final analysis all patients
were able to finish the whole course of TSEBT with moderate
side effects.
Combined treatment appears to be also safe and more
efficient for this group of patients. Quiros et al. [25], from
Yale University, in a retrospective study, reported the results
from 114 T1/T2 patients treated with TSEBT and adjuvant
oral psoralen plus ultraviolet light (PUVA). They observed a 5-
year overall survival of 100% in the group that received PUVA
versus 82% for the non-PUVA group (p < 0.10). The 5-year dis-
ease free survival for the entire cohort was 53%. Those who
received PUVA had a higher 5-year disease free survival (85%
versus 50%, p < 0.02), demonstrating that PUVA is an effective
adjuvant therapy with acceptable toxicity. Similar results had
already been shown by the Canadian study [11].
A retrospective analysis from Stanford University [26] pre-
sented the results of 148 patients: 55 patients with T2 and 27
with T3 disease that received TSEBT with or without topical
nitrogen mustard (HN2), and 54 patients with T2 and 12 with
T3 disease that received HN2 alone. Adjuvant HN2 improved
the 10-year relapse free survival rate: 40% versus 10% for
TSEBT alone. There was also an improvement in the complete
response rates for the TSEBT + HN2 group (76% versus 39%;
p = 0.03) in patients with T2 disease. However, no significant
differences in survival were observed for different manage-
ment programs for T2 or T3 disease.
Some phase II studies indicate favorable increases in com-
plete response rates and freedom from relapse when addingdiotherapy 1 9 ( 2 0 1 4 ) 92–98
interferon- to PUVA in the management of T2 patients
[27–29].
Clinical results and toxicity of TSEBT for early stage are
summarized in Table 1.
4.3.  Advanced  Stage  disease:  T3N0-1M0  (IIB);
T4N0-1M0  (III);  IV  and  palliation
Patients with advanced disease require a more  aggressive ther-
apeutic modality. Treatment options vary depending on the
characteristics of the lesions and previous treatments [30].
Nonetheless, a randomized trial demonstrated that there is
no advantage of early aggressive therapy (with chemotherapy)
versus conservative sequential therapy [31].
Skin tumors are favorably managed with radiotherapy due
to its ability to treat the full thickness of deeply infiltrated
skin. Most T3 patients present with extensive, symptomatic
tumors, and the majority will die from complications of the
disease [32,33].
This group frequently benefits from TSEBT as first line.
The outcomes regarding complete response rates are superior
when compared with topical HN2 plus localized RT (44–54%
versus 8%) [11,26].
The prospective French study [28] had 30% (20 patients)
stage C cases (IIB, IIIA, IIIB, IVA and IVB). All patients achieved
an important symptoms relief after TSEBT. The 5-year survival
rate was 44% and the complete response rate, 39%. There were
47% partial responses.
The Danish study [15] which compared low versus high
dose TSEBT also presented results of T3 patients (48.6% of the
studied patients) treated with 30 Gy TSEBT. Complete response
of 78.6%, partial response of 21.4% and a 37.5% rate of dis-
ease progression were observed. Freedom-from-progression
rates after 0.5-, 1- and 2-years were 92.3%, 75.2% and 62.7%,
respectively, in patients with T3 disease.
Adjuvant therapy must, however, be considered for
patients who achieve a complete response after TSEBT. The
Stanford University retrospective [30] series demonstrated
that the use of TSEBT plus topical HN2 yielded significantly
higher complete response in T3 patients when compared with
no HN2 (4% versus 8%, p < 0.05 for T3, respectively). They also
stated that TSEBT is an effective treatment for T3 disease
and emphasize that the adjuvant treatment may improve the
duration of response, resulting in a 5-year relapse free sur-
vival rate of 55% versus 30% with TSEBT alone. A small subset
of patients with limited T3 disease may also need to be treated
with HN2 and local RT for the tumors.
In another retrospective series from Navi et al. [34], 180
patients with T2/T3 MF disease were analyzed. They presented
a complete response rate, progression free survival and 5-year
overall survival of 36%, 29% and 44% for T3 patients, respec-
tively. Patients were treated with TSEBT (30–36 Gy) with or
without HN2 and, as side effect, moderate radiation induced
dermatitis was observed. The authors concluded that 30 Gy
was highly effective and that there was no clinical advan-
tage of HN2. Other adjuvant treatments that could be used are
photopheresis, bexarotene, interferon-, and denileukin difti-
tox [35,36]. However, the role of adjuvant therapy in overall
survival is still uncertain [13,29,37].
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Table 1 – Summarized clinical data for early stage (T1/T2N0) mycosis fungoides.
STUDY N METHODS CR DFS/PFS OS SKIN TOXICITY
Jones et al. (1995)a [10] 143 TSEBT >90% 15-y: CSS 96% 15-y: 76%
Quiros et al. (1997)
[25]
114 TSEBT 36 Gy 1 month: 97%(T1) 5-y: 53% 5-y: 85% Dry skin/erythema





40 TSEBT 35 Gy 4–5 weeks: 87% 2-y: 66% Acute: G II 0%
48 months: 27% Late: skin atrophy 87%
Ysebaert et al. (2004)
[22]
57 TSEBT 30 Gy T1 88% 1-y: 54,4% skin
failure
5-y: 90% Grade 1–2: 75.5%
T2 85% 10-y:  65% Grade 3: 24.5%
Mild edema: 10%
N: number of patients; CR: complete response; DFS: disease free survival; PFS: progression free survival; OS overall survival; TSEBT: total skin






































Most patients with stage IIB MF  will develop recurrence
fter complete response to initial treatment. Relapsed patients
ay be saved by systemic treatments such as retinoids,
istone deacetylase, interferon alfa, and denileukin diftitox
30,38,39]. Local persistent tumors could respond to additional
oses of local RT (boost) [17].
Due to its ability to produce a rapid and sustained response,
SEBT seems to be an appropriate initial therapy for T4
atients. Jones et al. [40] presented retrospective data from 28
tage III patients (T4 N0-1 M0), 13 with stage IVA (T4 N2-3 M0), 4
ith stage IVB (T4 N0-3 M1)  disease, and 21 with blood involve-
ent. The median radiation TSEBT dose was 32 Gy. The 5-year
rogression free survival was 69% for patients with T4N0M0
F disease. Toxicities of radiotherapy were acceptable.
Maingon et al. [41], in a retrospective study of advanced
F, described the results of TSEBT combined with photon
eam irradiation in 45 patients. The overall response rate was
1% for T3 patients, 61% for T4, 79% for N1 and 70% for N3.
he 5-year actuarial overall survival was 37% for T3 and 44%
or T4 (p = 0.84). Indeed, they demonstrated that patients with
dvanced disease might be treated with the addition of photon
eams to TSEBT, with good results.
Although, for patients with blood involvement, there is no
vidence that TSEBT can result in a significant malignant cells
ecrease in the circulation blood, potentially altering the nat-
ral history of the disease in patients B1 or B2 [42]. TSEBT is
n optional approach but it should be used carefully because
evere skin toxicity is normally observed (desquamation with
otal doses as low as 4 Gy) [34].
In palliative perspective in which there is extensive skin
nd extra-cutaneous disease or recurrence after the first radio-
herapy treatment course, TSEBT is still an option presenting
enefits with acceptable toxicity.
Funk et al. [43] analyzed the palliation effect of TSEBT in 18
atients with cutaneous T-cell non-Hodgkin’s lymphoma in
dvanced stages (IIB – IV) (72% MF)  refractory to prior treat-
ents. The median total dose was 25 Gy, and the median
ollow-up was 11 months. Fifty percent of patients achieved
 complete response, and 39%, partial response. At 1 year, the
rogression-free survival was 24% and the overall survival was
8%. All patients had moderate acute side effects. An update of
his study with 25 patients concluded that TSEBT is an efficientand well-tolerated considerable treatment option [44]. Some
case report [45] for stage IV symptomatic MF showed a com-
plete response of 100% at an 18 month-follow up with low
dose TSEBT. An institutional series [46] of 49 (which included
IV stage MF)  patients treated with TSEBT showed 38,8% and
45% rate of skin relapse and 10 years skin relapse free survival,
respectively.
A Yale University study [47] with the purpose to evalu-
ate the efficacy and toxicity of additional TSEBT for recurrent
lesions analyzed a total of 14 patients treated with at least two
courses of TSEBT, with five of those patients receiving a third
course with a median follow up of 36 months. The mean doses
for the first, second and third courses of TSEBT were 36 Gy,
18 Gy and 12 Gy respectively. Thirteen patients (93%) achieved
a complete response after the initial course. After the second
course, 12 patients (86%) had a complete response; of the five
patients who underwent a third course, three (60%) achieved
a complete response. The median disease-free interval after
the first course of therapy for those with a complete response
was 20 months and 11.5 months after the second course.
Median survival after the second course was 15 months. The
treatment was well tolerated beside the fact that all patients
presented skin side effects.
Becker et al. [48] from Stanford University published results
from a retrospective analysis of 15 patients with MF  that
relapsed. All received two courses of high-dose electron beam
therapy to the skin and adjuvant therapies between the first
and second courses. The mean dose for the total skin treat-
ment was 32.6 Gy for the first course and 23.4 Gy for the second
course. Eleven of the 15 patients had a complete response after
the first course, with a mean duration of 11.6 months. The
second course of therapy resulted in six complete and nine
partial responses. Late toxicity observed was restricted to skin
dryness, telangiectasias, pigmentation changes and alopecia.
Thus, for MF  patients delivering two courses of total skin
electron beam therapy is technically feasible, tolerable, and
efficacious. The criteria used to screen patients included initial
good response to total skin electron treatment, long disease-
free interval, exhaustion of other therapeutic modalities, and
generalized skin involvement at relapse.
Clinical results and toxicity of TSEBT for advanced stage
are summarized in Table 2.
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Table 2 – Summarized clinical data for advanced stage mycosis fungoides.
Study Population Methods CR DFS/PFS OS Toxicity
Harrison et al. (1997)
[56]
102 patients TSEBT 5–36 Gy T2 96% >30 Gy >30 Gy
T2/T3/T4 T3 96% T2 8.5 y T2 13.2 y
T3 2.9 y T3 4.8 y
Chinn et al. (1999)
[26]
148 patients TSEBT (30–36 Gy)
−/+ HN2
TSEBT + HN2: 76% 5-y 40% (T2) 5y:77%/44% (T2/T3) Dry skin/erythema
14% skin cancer
T2/T3 5-y 15–20% (T3) 10-y 41%/28% (T2/T3)
Navi et al. (2011) [34] 180 patients TSEBT (30–36 Gy)
−/+ HN2
T2:77% T2: 8.5 y 5-y: 63% Moderate radiation
induced dermatitis
T2/T3 T3: 36% T3: 2.9 y
10-y 44%
Kirova et al. (1999)
[24]
66 patients TSEBT 30 Gy 65% 5-y: 30% 5 y: 93–44% Acute: erythema
T3/T4 10-y 18%
Lindahl et al. (2011)
[53]
35 patients TSEBT 30 Gy 78.6% 0.5 y 92,3%
T3 1-y 75.2%
2-y 62.7%















[1CR: complete response; DFS: disease free survival; PFS: progression f
HN2: topical nitrogen mustard.
5.  Conclusions
TSEBT can be used to treat the whole skin in any stage of MF.
Re-irradiation also seems to be safe in persistent or recurrent
disease even after other therapeutic approaches, with good
response rates. TSEBT is generally well tolerated, but some
side effects are present. Temporary loss of toe/finger nails,
localized anhydrosis, rarely mild epistaxis, and parotiditis are
some acute sides effects [18,49,50]. Persistent nail dystrophy,
xerosis, telangiectasias, permanent partial alopecia, finger-
tip anesthesia, and possible infertility in male patients can
appear as chronic effects [54,55]. Secondary cutaneous malig-
nant diseases have been observed in patients treated with
TSEBT, particularly in those exposed to multiples therapies
[51,52].
The low numbers of patients in the studies and only one
randomized trial found in this review reflects the scarcity of
the disease. So, better evidence-based approaches will be dif-
ficult to be developed. At present, diminishing the skin side
effects that are tolerable but may impair quality of life should
be one of the goals for future research as new treatments asso-
ciations or targeted therapies.
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